Baig Mohammad H, Balaramnavar Vishal M, Wadhwa Gulshan, Khan Asad U
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
School of Biotechnology, Yeungnam University, Gyeongsan, Republic of Korea.
Biotechnol Appl Biochem. 2015 Sep-Oct;62(5):669-80. doi: 10.1002/bab.1370. Epub 2015 Jul 2.
TEM and SHV are class-A-type β-lactamases commonly found in Escherichia coli and Klebsiella pneumoniae. Previous studies reported S130G and K234R mutations in SHVs to be 41- and 10-fold more resistant toward clavulanic acid than SHV-1, respectively, whereas TEM S130G and R244S also showed the same level of resistance. These selected mutants confer higher level of resistance against clavulanic acid. They also show little susceptibility against other commercially available β-lactamase inhibitors. In this study, we have used docking-based virtual screening approach in order to screen potential inhibitors against some of the major resistant mutants of SHV and TEM types β-lactamase. Two different inhibitor-resistant mutants from SHV and TEM were selected. Moreover, we have retained the active site water molecules within each enzyme. Active site water molecules were placed within modeled structure of the mutant whose structure was unavailable with protein databank. The novelty of this work lies in the use of multilayer virtual screening approach for the prediction of best and accurate results. We are reporting five inhibitors on the basis of their efficacy against all the selected resistant mutants. These inhibitors were selected on the basis of their binding efficacies and pharmacophore features.
TEM和SHV是常见于大肠杆菌和肺炎克雷伯菌中的A类β-内酰胺酶。先前的研究报道,SHV中的S130G和K234R突变对克拉维酸的耐药性分别比SHV-1高41倍和10倍,而TEM的S130G和R244S也表现出相同水平的耐药性。这些选定的突变体对克拉维酸具有更高水平的耐药性。它们对其他市售的β-内酰胺酶抑制剂也几乎没有敏感性。在本研究中,我们使用了基于对接的虚拟筛选方法,以筛选针对SHV和TEM型β-内酰胺酶的一些主要耐药突变体的潜在抑制剂。从SHV和TEM中选择了两种不同的抑制剂耐药突变体。此外,我们保留了每种酶活性位点的水分子。活性位点水分子被放置在突变体的模拟结构中,其结构在蛋白质数据库中不可用。这项工作的新颖之处在于使用多层虚拟筛选方法来预测最佳和准确的结果。我们根据五种抑制剂对所有选定耐药突变体的疗效进行了报道。这些抑制剂是根据它们的结合效力和药效团特征选择的。